|
Genflow Biosciences PLC - London-based biotechnology firm, which has research facilities in Belgium - Launches new ophthalmology development programme, focused on advancing a novel gene therapy via its proprietary gene technology. The therapy will use a specially designed non-viral vector engineered for precise delivery of Genflow’s SIRT6 to the eye. It is designed to counter ocular problems including several pathologies of the cornea and glaucoma. Chief Executive Officer Eric Leire says: ‘We are thrilled to advance our ophthalmology program. The eye, as a closed and accessible compartment, presents an ideal target for gene therapy. More importantly, we believe that SIRT6 holds significant promise to transform the treatment landscape for corneal endothelial disorders and glaucoma.’ Current stock price: 1.01 pence each, up 1.0% on Thursday afternoon in London 12-month change: down 41% Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
